Compare LFMD & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | ETON |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | 384 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 689.8M |
| IPO Year | N/A | 2018 |
| Metric | LFMD | ETON |
|---|---|---|
| Price | $4.26 | $34.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $9.14 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 994.1K | 354.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $17.52 | $40.90 |
| Revenue Next Year | $18.73 | $47.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $2.60 | $13.09 |
| 52 Week High | $15.34 | $34.67 |
| Indicator | LFMD | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 74.36 |
| Support Level | $3.39 | $16.17 |
| Resistance Level | $5.25 | N/A |
| Average True Range (ATR) | 0.32 | 2.11 |
| MACD | -0.09 | 0.35 |
| Stochastic Oscillator | 7.72 | 98.99 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.